Ross Rheingans-Yoo

In this discussion, Ross Rheingans-Yoo, an expert in drug development, delves into the complexities of drug approval processes, revealing systemic inefficiencies and the evolving landscape of clinical trials. He reflects on historical events like the thalidomide crisis and how they shaped FDA policy, while also highlighting the impact of the AIDS epidemic and COVID-19 on accelerated approvals. Ross shares his innovative work in rescuing abandoned drugs and emphasizes the need for integrating technology into medicine to enhance patient care and streamline drug development.